Aptose Now In 'Hurry Up And Wait' Mode

Drug development takes time, patience, and careful attention to detail, and if you follow biotech investor message threads, you’ll see that’s not exactly a perfect match between industry and its investors. While biotech investors want a steady stream of positive news and updates, the reality is that sometimes there will be dry patches as the companies do their work. Such may well be the case now for Aptose Biosciences (APTO).

These shares have pulled back about 40% from their post-ASCO peak, but without much in the way of real news. Aptose announced the expected lifting of the clinical hold on APTO-253, but since then I believe the shares have weakened on relatively weak prospects for meaningful incremental updates and worries that Aptose would raise substantial new capital. While second quarter results should put the capital-raising question temporarily to rest, investors need to accept that there likely won’t be a lot of news until later this year and into 2019.

Read more here:
Aptose Now In 'Hurry Up And Wait' Mode